Despite the continuing turbulence in the global capital markets investors have had no qualms about backing the biotech sector – more in public biotechs than in private ones, however. The average increase in the stock values of the 231 public biotech companies tracked by the BioWorld Stock Report is up 38 percent year-to-date. Read More
Threshold Pharmaceuticals Inc.'s data for TH-302 in pancreatic cancer isn't perfect, but the biotech and its partner Merck KGaA think the Phase IIb results are good enough to justify pushing the drug into a Phase III trial for the indication. Read More
What a difference a year makes. When biotechnology execs and investors converged on the Palace Hotel in San Francisco last year for the two-day annual BIO Investor Forum, the biotech sector had just come through a tough third quarter in terms of fundraising, with public and private financings for the industry down 48 percent compared to 2010. Read More
